NP has said Kelly introduced him to Klump who introduced him to Patterson. The thought is without Kelly, no Patterson, maybe. Not sure if Kelly adds much more. I was disappointed with the share awards for BTD for cancer. If NP delivers CV and cancer, I am now totally fine with him getting it. Personally, the rest of the award should go to Patterson though, not BOD.

The FDA is taking their standard stance. They could end the trial early with strong efficacy and approve. We need to get enrolling fast. Gilead started a month before us and has lobbyists. Plus they have the direct antiviral mechanism that Fauci ,CDC, and FDA seems to favor. Leronlimab is immunodulation with secondary antiviral effect through T cells--the much better mechanism. All just IMO.